GlassScriptPhysician profile
Brittany C Dobi
NPI 1013206960
$13,594.26
in general payments reported to CMS, 2019-2025
24 companies · $7,422 in 2025
The $7,422 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.65 · 2020: $132 · 2021: $477 · 2022: $545 · 2023: $419 · 2024: $4,552 · 2025: $7,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,600.00 |
| Food and Beverage | $792.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $11,617.54 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $609.81 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $207.65 | 2021-2025 | |
| Organon LLC | $179.82 | 2021-2025 | Jada System, Nexplanon |
| Daiichi Sankyo INC. | $164.26 | 2022-2023 | Injectafer |
| Astellas Pharma US INC | $133.75 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $133.25 | 2021-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $88.84 | 2023-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Avion Pharmaceuticals | $73.41 | 2021-2022 | |
| Exeltis, USA INC. | $62.65 | 2022-2023 | Slynd |
| Millicent US INC | $47.98 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Minerva Surgical, INC | $46.66 | 2022-2023 | |
| Pfizer INC. | $41.48 | 2023-2024 | |
| Avanos Medical | $26.47 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.98 | 2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $19.04 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.56 | 2021 | |
| Duchesnay USA Incorporated | $17.41 | 2019 | |
| Dysis Medical, INC. | $16.66 | 2022 | |
| Therapeuticsmd, INC. | $15.34 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.78 | 2021 | |
| Ethicon US, LLC | $14.38 | 2023 | Surgicel Nu-Knit |
| Allergan, INC. | $13.59 | 2020 | |
| Merck Sharp & Dohme LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Dobi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.